Curriculum vitae: *) Personal data:

Name: Slavko M. Janković, M. D., Ph. D.

Address: ***** ********

Work: Clinic of neurology, Serbia

Tel.: INT.+381-**-*******

E-mail: acr2o6@r.postjobfree.com

Neuropsychiatrist,

Subspecialist in clinical neurophysiology and epileptology,

Certified ESRS somnologist, expert in sleep medicine,

President, Serbian Sleep Society (full member of ESRS)

Web: http://www.sss.rs

Clinic of neurology, Clinical center of Serbia,

11000 Belgrade, Dr Subotica Street # 6, Serbia

Tel: +381-**-*******

Email: acr2o6@r.postjobfree.com

http://neurologija.bg.ac.rs/

Date of birth: June 9, 1952.

Place of birth: Belgrade,

Country of birth: Serbia

Marital status: married,

Children: two sons

Languages spoken: English, German, Serbian (Bosnian, Croatian, Montenegro)

2) Education:

1959-1967: Elementary school

1967-1971: Belgrade high school (Gymnasium)

1971-1978: University of Belgrade, School of Medicine (Medical doctor)

1983-1985: University of Belgrade, Institute for Biological Research - Magister of Sciences (Mr Sci.). Thesis title: "The interrelationship of penicillin epilepsy and deprivation of paradoxical sleep phase in cats".

1983-1987: University of Belgrade, School of Medicine- specialist in neuropsychiatry.

1986-1987: University of Belgrade, School of Medicine- certified electroencephalo-grapher and clinical neurophysiologist.

1991-1994: University of Belgrade, School of Medicine- Doctor of medical Sciences (Ph. D.). Thesis title: "Analysis of clinical and subclinical paroxysms, sleep and sleep deprivation in epileptic patients".

2006: Subspecialist in Epileptology and Clinical Neurophysiology with somnology.

2013: (exam in Berlin, Germany) Certified ESRS somnologist, expert in sleep medicine (grandfathering process).

3) Traineeship:

Internship: 1 year

Resident: 2 years

Registrar: 2 years

Senior Registrar: 2 years

Consultant: 27 years

4) Board qualifications:

A) Serbian Board of Neurology and Psychiatry

B) Certified electroencephalographer and polysomnographer

C) Subspecialist in clinical neurophysiology with epileptology, Serbia

D) Good Clinical Practice certificate (2009).

E) Certified ESRS somnologist, expert in sleep medicine (2013).

5) Memmbership and Activities:

International Societies membership:

1) European Neuroscience Association (ENA) since 1984.

2) European Brain and Behavior Society (EBBS) since 1985.

3) International Brain Research Organization (IBRO) since 1986.

4) World Association of Sleep Medicine (WASM) since 2011.

5) European Sleep Research Society (ESRS), since 2012.

National Societies membership:

1) Yugoslav Medical Society (since 1978)

2) Yugoslav Medical Society, Section for Neurology (since 1987).

3) Yugoslav Society for Neuroscience (since 1988).

4) Yugoslav Medical Society, Section for EEG and Clinical Neurophysiology (since 1983).

5) Serbian Sleep society (since 2011).

National activities:

1) Secretary, Section for EEG and Clinical Neurophysiology of Yugoslavia.

2) Secretary, "Journal of Clinical and Experimental Neurology" (official Journal of Yugoslav Neurological Society).

3) President, Serbian Sleep Society, 2011 (http://www.sss.rs)

International activities:

1) Yugoslav chapter of ILAE correspondent to "Epigraph", (The Newsletter of the International League Against Epilepsy).

6) Hospital appointments:

1981- 1983: General practitioner

1983- 1985: Clinical research fellow (resident)

1985- 1986: Registrar

1986- 1987: Senior Registrar

1987: Consultant

1990- 1992: Chief, Laboratory for EEG

1992- Department for Sleep and Epilepsy Research, Clinic of Neurology, Belgrade, Serbia

2004- Chief, Laboratory for sleep research, Clinic for Neurology, Clinical Center of Serbia

7) Honors:

1987-1994: Secretary, Section for EEG and Clinical Neurophysiology of Yugoslavia

1994-1997: Treasurer, Union of Yugoslav Societies for EEG and Clinical Neurophysiology

1996: Secretary, "Journal of Clinical and Experimental Neurology" (official Journal of Yugoslav Neurological Society).

1996: Scientific advisor in Neurology (Institute of Neurology, Belgrade)

1997: Secretary, Section for EEG and Clinical Neurophysiology of Yugoslavia.

2000: Primarius (Institute of Neurology, Belgrade)

2011. President of the “Serbian Sleep Society”

8) Fellowships and Grant supports:

- 1985: European Science Foundation Scientific Committee fellowship for the participation in "European Training Program in Brain and Behavior Research", University of Bergen, Institute of Physiological Psychology, Bergen, Norway.

- 1985: Scientific Committee for Epilepsy award: participation on the 16th Epilepsy International Congress in Hamburg, Germany.

9) Participation in clinical trials

1) Name of the study: An exploratory, double blind, randomized, placebo-controlled, parallel group, multicenter study, for the assessment of efficacy, safety and tolerability of ucb 34714 50 mg oral capsules in b.i.d. administration at the doses of 200 mg/day and 400 mg /day, in subjects (at least 18 years old) suffering from post-herpetic neuralgia (PHN). 2005. Coinvestigator.

2) Name of the study: A randomized, multi-centre, double-blind study, to compare the efficacy and safety of zonisamide and carbamazepine as monotherapy, in newly diagnosed partial epilepsy, 2007. Coinvestigator.

3) Name of the study: A randomized, double-blind, parallel-group, multi-center, comparative, flexible dose trial of Pregabalin versus Gabapentin as adjunctive therapy in subjects with partial seizures (A0081143).

Compound: A008. Compound name: Pregabalin. US IND Number: 53,763. Protokol number: A0081143. Phase: IV. Version and date: Amendment 2, 4. 2008. (Pfizer), Coinvestigator.

4) Name of the study: Protocol E2007-G000-307: An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Studies to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive Therapy in Subjects with Refractory Partial Seizures. (E2007-G000-306), 2008. Coinvestigator.

5) Name of the study: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Carisbamate as Adjunctive Therapy in Subjects with Partial Onset Seizures, Followed by an Open-Label Extension Study (RWJ-333369).

Protokol: CARIS-EPY-3013/3014. Faza: III. Sponzor: Janssen-Cilag International N.V.,Turnhoutseweg 30, B-2340 Beerse, Belgija, koga zastupa predstavništvo Johnson and Johnson SE Inc, Beograd, Omladinskih brigada 88B, 11070 Novi Beograd, Srbija. 2009. Coinvestigator.

6) Name of the study: Protocol 093-046. Double-blind, Randomized, Historical Control Study of the Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects with Partial Epilepsy not well Controlled by Current Antiepileptic Drugs.

( Dvostruko-slepo, randomizovano, istorijski kontrolisano ispitivanje bezbednosti i efikasnosti monoterapije eslikarbazepin acetatom kod ispitanika sa parcijalnom epilepsijom koja nije dobro kontrolisana trenutno korišćenim antiepilepticima“), 2011, Coinvestigator. 2011.

7) Name of the study: Clinical Study Protocol Spinifex Pharmaceuticals Protocol No. EMA401-003. Protocol Title: A double-blind, placebo-controlled, randomised trial to prove the therapeutic concept and to determine the safety, tolerability and pharmacokinetic profile of EMA401 (angiotensin II type 2 receptor antagonist) administered orally in patients with postherpetic neuralgia. Coinvestigator.

Lay Person Protocol Title: A study of oral EMA401 in the treatment of pain following shingles to see if EMA401 can reduce the level of pain.

Protocol No. EMA401-003. Phase IIa.

8) Name of the study: An open-label, multi-center follow-up trial to evaluate long-term safety and efficacy of brivaracetam (ucb 34714) used as adjunctive treatment at a flexible dose up to a maximum of 200 mg/day in subjects aged 16 years or older suffering from epilepsy. (Otvoreno, multicentrično ispitivanje praćenja u cilju procene dugoročne bezbednosti i delotvornosti Brivaracetama (ucb 34714) kao dopunske terapije primenom fleksibilne doze do najviše 200 mg dnevno kod ispitanika sa epilepsijom od 16 godina i starijih). Coinvestigator.

Protokol: UCB_No1125. Sponzor: UCB S.A. – Pharma Sector R&D. Chemin Du Foriest 81420 Braine l’ Alleud, Belgium. CRO: PPD Serbia D.O.O, Ljubostinjska 2, 11000 Beograd, Serbija.

9) Name of the study: Double blind, randomized, placebo controlled, multicenter, paralell group study with an open-label extension phase to evaluate the efficacy and safety of adjunctive Perampanel in primary generealized tonic clonic seizures. Sponsor: EISAI. 2012. Protocol number: E2007-G000-332.

10) Name of the study: Efficacy And Safety Of Eslicarbazepine Acetate (Bia 2-093) As Monotherapy For Patients With Newly Diagnosed Partial-Onset Seizures: A Double-Blind, Randomized, Active-Controlled, Parallel-Group, Multicenter Clinical Study. 2012. Study Number: BIA-2093-311. Study Product: Eslicarbazepine acetate. EudraCT Number: 200*-******-**. (Naziv studije: Efikasnost i bezbednost eslicarbazepine acetate a (bia 2 093) kao monoterapije kod pacijenata sa novo dijagnostikovanim parcijalnim napadima: dvostruko slepa, randomizovana, aktivno – kontrolisana, multicentrična klinička studija sa paralelnim grupama), 2012.

11) Name of the study: MESS Study. Multicentre Study of Early Epilepsy and Single Seizures (MESS): Obtaining Final Follow-up Data of MESS Study, Walton Centre for Neurology & Neurosurgery, February, 2002- Collaborator.

12) Name of the study: EURAP Study. Europian (International) registry of Antiepileptic Drugs and Pregnancy. International prospective observational study. prospective observational study. 2000- Collaborator.

13) Name of the study: BF2.649 in patients with Obstructive Sleep Apnoea syndrome (OSA), and treated by nasal Continuous Positive Airway Pressure (nCPAP), but still complaining of Excessive Daytime Sleepiness (EDS) – Phase III. Protocol P 09-08/BF2.649–HAROSA I. EudraCT number: 200*-******-**. (2011). Primary investigator.

14) Name of the study: Efficacy and safety of BF2.649 in the treatment of Excessive Daytime Sleepiness in patients with Obstructive Sleep Apnoea syndrome (OSA) refusing the nasal Continuous Positive Airway Pressure (nCPAP) therapy. Protokol P 09-09 / BF 2.649. EudraCT br: 200*-******-**. (2013). Primary investigator.

15) Name of the study: A randomized, double blind study comparing BF2.649 (Pitolisant) to placebo in two parallel groups on the weekly frequency of cataplexy attacks and Excessive Daytime Sleepiness in narcoleptic patients with cataplexy. Protocol P 11-05 HARMONY CTP / BF 2.649. (2012). Primary investigator.

16) Name of the study: SK Life Sciences study: YKP3089C017: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Response Trial of YKP3089 as Adjunctive Therapy in Subjects with Partial Onset Seizures, with Optional Open-Label Extension.

10) Selected recent Publications:

1. S. Janković, D. Sokić, N. Vojvodić, A. Ristić, V. Kostić. The First Cinematic Presentation of a Possible Rhythmic Movement Disorder in a Disney Film Precedes Its Scientific Debut by 60 Years. Movement Disorders. Vol 24, No I 138-151, 2009.

2. S. Janković, D. Sokić, N. Vojvodić, A. Ristić, V. Kostić. Multiple Rhythmic Movement Disorders in a Teenage Boy with Excellent Response to Clonazepam. Movement Disorders. Vol: 23, Issue 5, p: 767-768. 2008.

3. Jankovic SM, Sokic DV, Vojvodic NM, Ristic A. The First Film Presentation of REM Sleep Behavior Disorder Precedes Its Scientific Debut By 35 Years. Srp Arh Celok Lek. (9-10): 466-469, 2006.

4. S M Jankovic, D V. Sokic, N M. Vojvodic, A J. Ristic, V S. Kostic, Lj M. Zovic. Rhythmic head movements in a horse reminiscent to human head banging rhythmic movement disorder. Swiss Archives of Neurology and Psychiatry, 161(4), 2010.

5. D.V. Sokic, S.M. Jankovic, N.M. Vojvodic, A.J. Ristic Etiology of a short-term mortality in the group of 750 patients with 920 episodes of status epilepticus within a period of 10 years (1988–1997). Seizure. 18: 215–219, 2009.

6. A. J. Ristic, D. V. Sokic, G. Trajkovic, S. Jankovic, N. M. Vojvodic, V. Basarevic, Lj. M. Popovic Long-term survival in patients with status epilepticus: Epilepsia. Published Online: Jun 26 2009 10:29AM, DOI: 10.1111/j.1528-1167.2009.02188.x

7. M. Kecmanović, A. Ristić, D. Sokić, M. Keckarević-Marković, N. Vojvodić, M. Ercegovac, S. Janković, D. Keckarević, D. Savić-Pavićević, and S. Romac. Coexistence of Unverricht-Lundborg disease and congenital deafness: Molecular resolution of a complex comorbidity. Epilepsia, Vol 50, Issue 6, Pages: 1612-1615, 2008.

8. Sokic D, Ristic AJ, Vojvodic N, Jankovic S, et al. Frequency, causes and phenomenology of late seizure recurrence in patients With juvenile myoclonic epilepsy after a long period of remission. Seizure;16:533-537, 2007.

9. Ristić A, Vojvodić N, Janković S, Sindjelić A, Sokić D. The Frequency of Reversibile Parkinsonism and Cognitive Decline Associated with Valproate Treatment: a Study of 364 Patients with Different Types of Epilepsy. Epilepsia; 47 (12): 2183-2185, 2006.

10. A Marson, A Jacoby, A Johnson, L Kim, C Gamble, D Chadwick, on behalf of the Medical Research Council MESS Study Group (International study group, multicentric study: Medical Research Council MESS Study Group, Dr S. M. Jankovic). Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomised controlled trial. Lancet; 365(9476): 2007–13, 2005.

11. N Vojvodic, DV Sokic, S Jankovic and S Delic. Isolated episodes of status epilepticus as the manifestation of neurosyphilis. Epilepsia, Vol 44, No 4, p. 623, 2003.

12. Goncalves M, Amici R, Lucas R, et al. (S. Jankovic, as a collaborator). Sleepiness at the wheel across Europe: a survey of 19 Countries. J Sleep Res. (2015) 24, 242–253 DOI: 10.1111/jsr.12267

13. S Janković, D Sokić, N Vojvodić, A Ristić, M Kovačević. A Somnologist’s Flashback on Edgar Allan Poe’s The Premature burial. Sleep Medicine Reviews, 2015 (in press)

Contact this candidate